Analysts predict that Heska Corp (NASDAQ:HSKA) will announce sales of $34.29 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Heska’s earnings. The lowest sales estimate is $34.21 million and the highest is $34.36 million. Heska posted sales of $34.06 million in the same quarter last year, which suggests a positive year over year growth rate of 0.7%. The company is scheduled to report its next earnings report on Tuesday, February 25th.

On average, analysts expect that Heska will report full year sales of $123.18 million for the current financial year, with estimates ranging from $123.11 million to $123.25 million. For the next fiscal year, analysts forecast that the business will post sales of $140.02 million, with estimates ranging from $138.76 million to $141.27 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Heska.

Heska (NASDAQ:HSKA) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). Heska had a net margin of 3.15% and a return on equity of 3.17%. The business had revenue of $31.24 million during the quarter, compared to analysts’ expectations of $30.44 million.

A number of equities analysts have commented on the stock. Raymond James cut shares of Heska from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. They noted that the move was a valuation call. Canaccord Genuity reissued a “buy” rating and issued a $105.00 price objective (up from $75.00) on shares of Heska in a research note on Wednesday, November 6th. Zacks Investment Research cut shares of Heska from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. Piper Jaffray Companies started coverage on shares of Heska in a research note on Wednesday, September 18th. They set a “neutral” rating and a $68.00 price target for the company. Finally, BidaskClub raised shares of Heska from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 27th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $85.75.

Hedge funds have recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. purchased a new position in shares of Heska during the 2nd quarter worth about $29,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Heska by 175.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 670 shares of the medical research company’s stock worth $47,000 after purchasing an additional 427 shares during the period. Aperio Group LLC purchased a new position in shares of Heska during the 2nd quarter worth about $79,000. Quantamental Technologies LLC purchased a new position in shares of Heska during the 2nd quarter worth about $120,000. Finally, Bank of Montreal Can boosted its stake in shares of Heska by 30.3% during the 2nd quarter. Bank of Montreal Can now owns 2,162 shares of the medical research company’s stock worth $183,000 after purchasing an additional 503 shares during the period. 97.92% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:HSKA traded down $0.61 on Wednesday, reaching $94.89. The company’s stock had a trading volume of 72,840 shares, compared to its average volume of 89,056. Heska has a 52-week low of $62.47 and a 52-week high of $104.99. The company has a market cap of $753.36 million, a P/E ratio of 66.82 and a beta of 1.08. The company has a 50-day simple moving average of $85.48 and a 200 day simple moving average of $78.07. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.80 and a current ratio of 8.52.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Recommended Story: What are popular green investing opportunities?

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.